EP3984994
Setið píperídín-efnasamband sem orexín-örvi af gerð 2 til meðferðar við drómasýki
:
EP einkaleyfi í gildi á Íslandi:
1.2.2017:
3.7.2024:
21209107.8
:
30.9.2024:
15.11.2024
:
31.1.2037:
31.1.2026:
28.2.2026
:
SUBSTITUTED PIPERIDINE COMPOUND AS OREXIN TYPE 2 AGONIST FOR THE TREATMENT OF NARCOLEPSY
1.2.2017
3.7.2024
30.9.2024
15.11.2024
31.1.2026
:
Takeda Pharmaceutical Company Limited:
1-1, Doshomachi 4-chome Chuo-ku, Osaka-shi, Osaka 541-0045, JP
:
FUJIMOTO, Tatsuhiko:
Fujisawa-shi Kanagawa, 251-0012, JP
:
RIKIMARU, Kentaro:
Fujisawa-shi Kanagawa, 251-0012, JP
:
FUKUDA, Koichiro:
Fujisawa-shi Kanagawa, 251-0012, JP
:
SUGIMOTO, Hiromichi:
Tokyo, 100-0005, JP
:
MATSUMOTO, Takahiro:
Fujisawa-shi Kanagawa, 252-0804, JP
:
TOKUNAGA, Norihito:
Fujisawa-shi Kanagawa, 251-0012, JP
:
HIROZANE, Mariko:
Fujisawa-shi Kanagawa, 251-0012, JP
:
Árnason Faktor ehf.:
Guðríðarstíg 2-4, 113, Reykjavík,
:
2016019834:
4.2.2016:
JP
:
C07D 211/24, C07D 211/36, C07D 211/56, C07D 401/06, C07D 401/12, C07D 401/14, C07D 405/06, C07D 405/12, C07D 405/14, C07D 409/06, C07D 409/12, C07D 413/06, C07D 417/06, C07D 417/14, A61P 25/00, A61K 31/435
: 9
: 24.1.2025
: 31.1.2026
: Árnason Faktor ehf.